Stay updated on Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page displays Revision: v3.6.3 in place of Revision: v3.6.2, indicating a version update to the page. This change represents a metadata refresh (e.g., template or content adjustments) without altering the study details presented.SummaryDifference0.0%

- Check23 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing the previous v3.6.0. This indicates a minor maintenance update to the page without altering study content.SummaryDifference0.0%

- Check37 days agoChange DetectedThe page now shows recruitment closed by displaying 'No longer looking for participants' and adds new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study). It also updates the Intervention/Treatment heading formatting and introduces a Revision: v3.6.0.SummaryDifference0.3%

- Check44 days agoChange DetectedRevision label changed from v3.5.4 to v3.5.5. This indicates a minor update to the page template or content without altering the study information.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, indicating a small backend update to the page without changes to the study information presented.SummaryDifference0.0%

- Check87 days agoChange DetectedThe page’s revision/version indicator in the footer has been updated from v3.5.2 to v3.5.3, reflecting a site release rather than a change to the study record details.SummaryDifference0.0%

Stay in the know with updates to Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.